KURA ONCOLOGY, INC. (KURA) scores 40 out of 100 on boothcheck's 11-model valuation framework. Verdict: Bad The estimated fair value is 0.16, representing a 98% premium to fair value. Quantitative score: 40/100. Qualitative score: 70/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.